Calox   Report issue

For profit Phase 3
Founded: San Jose Costa Rica (1935)
Status: No NME R&D (1935)

Organization Overview

First Clinical Trial
2019
NCT03901690
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CALOX Laboratories

Active Ingredients

Drugs in Phase 3 Trials (2)

beta-glucans (1 trial)

imiquimod (aldara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Condylomata Acuminata (Phase 3)

Virus Diseases (Phase 3)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2